episode 924: TWiV clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses Tecovirimat for treatment of monkeypox, the safety and acceptance of vaccination after multisystem inflammatory syndrome, variants in solid organ transplant recipients, masks for prevention of respiratory virus infections, pre-exposure prophylaxis with Evusheld, the association between Evusheld administration and infection, if repeat administration of casirivimab and imdevimab is well-tolerated, viral and symptom rebound in untreated infection, extended Remdesivir infusion for persistent infection, Baricitinib in patients admitted with infection, and cognitive impairment 13 months after hospitalization.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Armchair Expert with Malcolm Gladwell
- Tecovirimat for treatment of monkeypox (OFID)
- Safety and acceptance of vaccination after MIS (JPID)
- Is variant less virulent in solid organ transplant recipients (Transplant Infectious Disease)
- Masks for prevention of respiratory virus infections (Annals of Internal Medicine)
- Pre-exposure prophylaxis with Evusheld (CMI)
- Association between Evusheld administration and infection (CID)
- Repeat administration of casirivimab and imdevimab well-tolerated (ISID)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Viral and symptom rebound in untreated infection (medRxiv)
- Extended Remdesivir infusion for persistent infection (OFID)
- Baricitinib in patients admitted with infection (The Lancet)
- Cognitive Impairment 13 months after hospitalization (OFID)
- Contribute to Floating Doctors fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 924
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv